PrintOverview:
China's pharmaceutical market is a large, rising opportunity – reaching an estimated $38 billion in 2009 and still growing at almost 20% annually. By 2012, China should rank as the world’s third largest pharmaceutical market and is expected to grow to $100 billion by 2015. This makes it strategically crucial for Western pharmaceutical companies to succeed in China. However, the Chinese pharmaceutical market has unique characteristics which must be understood to make the China potential a reality.
This research report contains key information on multiple important topics of the Chinese pharmaceutical market, including market data, the role of government health insurance reimbursement, government price controls, institutional purchasing practices, differing characteristics and business strategies of domestic and foreign pharmaceutical companies, and more. It also includes three appendices: one on recent acquisitions, ventures, and partnerships in the Chinese drug industry; a list of all drugs which Chinese government health insurance will reimburse; and contact information for key Chinese drug agencies.
This report has 38 pages + a 54-page appendix.
Updates for 2011 include:
• Latest health and pharmaceutical market projections for China
• Recent Chinese healthcare reforms and their impact on foreign
medical investment
• Latest drug pricing policies impacting foreign pharmaceutical
companies
• Latest drug reimbursement policies affecting foreign drug demand
See
a sample page of this report.
Table of Contents
I. Introduction to ChinaII. Overview of China Pharmaceutical Market
A. China Healthcare System
B. Growth in Healthcare Spending
C. Pharmaceutical Sales
III. Health Insurance in China
A. Overview – Basic Medical Insurance
B. Other Public Health Insurance Systems
C. Private Health Insurance
IV. Drug Reimbursement System
A. Mechanics of Drug Reimbursement
B. Drug Reimbursement Lists
C. Who Controls Revisions to Drug Reimbursement Lists
D. When Reimbursement is Important
E. Strategies for Reimbursement List Entry
F. Other Developments - The Essential Drug List
V. Price Determination
VI. Hospital Purchasing and Prescribing
A. Hospital Tendering
B. Prescription Controls
VII. Foreign Pharmaceutical Companies in China
A. Overview
B. Trends
VIII. Domestic Chinese Pharmaceutical Companies
A. Overview
B. Domestic Pharmaceutical Companies’ Changing Strategies
IX. Pharmaceutical Distribution in China
X. Predicted Trends
A. Overview
B. Healthcare Providers
C. Healthcare Funding
D. Reimbursement System
E. Price Determination
F. Recent Regulatory Reforms
XI. Conclusion
Appendices:
Appendix A: Acquisitions, Ventures, and Partnerships in the Chinese Drug
Industry
Appendix B: National Reimbursement Drug List (2009), The National Essential
Drug List (2009)
Appendix C: Key Drug Agencies in China
Order now and we will ship you this report at no additional charge.
Price: $600
Please contact us at researchstore@pacificbridgemedical.com if you have any questions.